Fellowship & Membership

  • Member of European Society of Medical Oncology
  • Indian Society of Medical and Paediatric Oncologist
  • American Society of Clinical Oncology
  • Languages Spoken

  • English
  • Hindi
  • Bengali
  • Field of Expertise

  • Medical aspects of Solid Tumours and Haemato-lymphoid Malignancies
  • Medical management of Oncologic emergencies
  • Immunotherapy and targeted therapies in treatment of advanced malignancies
  • Awards & Achievements

  • Selected for presentations of research work (with scholarship) at numerous National and International Conferences including ESMO-Asia (Singapore) and ELCC (Geneva).
  • Invited as Speaker and Faculty/Panelist at numerous State and National-level Oncology Conferences organised by Institutions.
  • Talks & Publications

  • RESEARCH : INTERNATIONAL PRESENTATIONS AND PUBLICATIONS:
  • Liquid Biopsies in Clinical Oncology: Review of validation results: K. Gupta, A.Chougule, V. Ramprasad, V. Noronha, A. Joshi, V. Patil, V.H. Veldore, K. Prabhash, Medical Oncology, Tata Memorial Centre Hospital, Mumbai, INDIA (Presented at ESMO-Asia, Nov 17-19, 2017 at Singapore): Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx672.001, Click Here
  • Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results K. Gupta, A. Joshi, V. Noronha, S.K. Parthiban, V.M. Patil, A. Janu, R. Kaushal, K. Prabhash; Medical Oncology, Tata Memorial Hospital Centre, Mumbai, INDIA ( Presented at ELCC, Geneva, April 11-14,2018): Journal of Thoracic Oncology Apr 2018 Volume 13, Issue 4, Supplement, Page S91
  • Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. K.Gupta, V. Noronha, A.Joshi, V.M. Patil, S.Parthiban, S.Srinivas, D.H.Vallathol, A.Mahajan, A.Janu, K.Prabhash May 2018, Journal of Clinical Oncology 36(15_suppl):e15065-e15065 DOI: 10.1200/JCO.2018.36.15_suppl.e15065
  • Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. Anant Ramaswamy, Vikas Ostwal, Kushal Gupta, et al. October 2018, South Asian Journal of Cancer 7(4):219 DOI: 10.4103/sajc.sajc_232_17
  • Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer (Co-author). Patil V, Joshi A, Noronha V, Dhumal S, et al.: Cancer Res Stat Treat 2018;1:46-50.
  • Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.(Co-author) May 2017 Journal of Clinical Oncology 35(15_suppl):6018-6018 DOI: 10.1200/JCO.2017.35.15_suppl.6018
  • Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retropsective analysis.(Presented at ESMO-Asia Conference , Singapore, Nov 2018) Annals of Oncology (2018) 29 (suppl_9): ix124-ix128. 10.1093/annonc/mdy443.

    Languages Spoken

  • English
  • Hindi
  • Bengali
  • Fellowship & Membership

  • Member of European Society of Medical Oncology
  • Indian Society of Medical and Paediatric Oncologist
  • American Society of Clinical Oncology
  • Field of Expertise

  • Medical aspects of Solid Tumours and Haemato-lymphoid Malignancies
  • Medical management of Oncologic emergencies
  • Immunotherapy and targeted therapies in treatment of advanced malignancies
  • Awards & Achievements

  • Selected for presentations of research work (with scholarship) at numerous National and International Conferences including ESMO-Asia (Singapore) and ELCC (Geneva).
  • Invited as Speaker and Faculty/Panelist at numerous State and National-level Oncology Conferences organised by Institutions.
  • Talks & Publications

  • RESEARCH : INTERNATIONAL PRESENTATIONS AND PUBLICATIONS:
  • Liquid Biopsies in Clinical Oncology: Review of validation results: K. Gupta, A.Chougule, V. Ramprasad, V. Noronha, A. Joshi, V. Patil, V.H. Veldore, K. Prabhash, Medical Oncology, Tata Memorial Centre Hospital, Mumbai, INDIA (Presented at ESMO-Asia, Nov 17-19, 2017 at Singapore): Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx672.001, Click Here
  • Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results K. Gupta, A. Joshi, V. Noronha, S.K. Parthiban, V.M. Patil, A. Janu, R. Kaushal, K. Prabhash; Medical Oncology, Tata Memorial Hospital Centre, Mumbai, INDIA ( Presented at ELCC, Geneva, April 11-14,2018): Journal of Thoracic Oncology Apr 2018 Volume 13, Issue 4, Supplement, Page S91
  • Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. K.Gupta, V. Noronha, A.Joshi, V.M. Patil, S.Parthiban, S.Srinivas, D.H.Vallathol, A.Mahajan, A.Janu, K.Prabhash May 2018, Journal of Clinical Oncology 36(15_suppl):e15065-e15065 DOI: 10.1200/JCO.2018.36.15_suppl.e15065
  • Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. Anant Ramaswamy, Vikas Ostwal, Kushal Gupta, et al. October 2018, South Asian Journal of Cancer 7(4):219 DOI: 10.4103/sajc.sajc_232_17
  • Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer (Co-author). Patil V, Joshi A, Noronha V, Dhumal S, et al.: Cancer Res Stat Treat 2018;1:46-50.
  • Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.(Co-author) May 2017 Journal of Clinical Oncology 35(15_suppl):6018-6018 DOI: 10.1200/JCO.2017.35.15_suppl.6018
  • Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retropsective analysis.(Presented at ESMO-Asia Conference , Singapore, Nov 2018) Annals of Oncology (2018) 29 (suppl_9): ix124-ix128. 10.1093/annonc/mdy443.

    Field of Expertise

  • Medical aspects of Solid Tumours and Haemato-lymphoid Malignancies
  • Medical management of Oncologic emergencies
  • Immunotherapy and targeted therapies in treatment of advanced malignancies
  • Fellowship & Membership

  • Member of European Society of Medical Oncology
  • Indian Society of Medical and Paediatric Oncologist
  • American Society of Clinical Oncology
  • Languages Spoken

  • English
  • Hindi
  • Bengali
  • Awards & Achievements

  • Selected for presentations of research work (with scholarship) at numerous National and International Conferences including ESMO-Asia (Singapore) and ELCC (Geneva).
  • Invited as Speaker and Faculty/Panelist at numerous State and National-level Oncology Conferences organised by Institutions.
  • Talks & Publications

  • RESEARCH : INTERNATIONAL PRESENTATIONS AND PUBLICATIONS:
  • Liquid Biopsies in Clinical Oncology: Review of validation results: K. Gupta, A.Chougule, V. Ramprasad, V. Noronha, A. Joshi, V. Patil, V.H. Veldore, K. Prabhash, Medical Oncology, Tata Memorial Centre Hospital, Mumbai, INDIA (Presented at ESMO-Asia, Nov 17-19, 2017 at Singapore): Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx672.001, Click Here
  • Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results K. Gupta, A. Joshi, V. Noronha, S.K. Parthiban, V.M. Patil, A. Janu, R. Kaushal, K. Prabhash; Medical Oncology, Tata Memorial Hospital Centre, Mumbai, INDIA ( Presented at ELCC, Geneva, April 11-14,2018): Journal of Thoracic Oncology Apr 2018 Volume 13, Issue 4, Supplement, Page S91
  • Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. K.Gupta, V. Noronha, A.Joshi, V.M. Patil, S.Parthiban, S.Srinivas, D.H.Vallathol, A.Mahajan, A.Janu, K.Prabhash May 2018, Journal of Clinical Oncology 36(15_suppl):e15065-e15065 DOI: 10.1200/JCO.2018.36.15_suppl.e15065
  • Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. Anant Ramaswamy, Vikas Ostwal, Kushal Gupta, et al. October 2018, South Asian Journal of Cancer 7(4):219 DOI: 10.4103/sajc.sajc_232_17
  • Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer (Co-author). Patil V, Joshi A, Noronha V, Dhumal S, et al.: Cancer Res Stat Treat 2018;1:46-50.
  • Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.(Co-author) May 2017 Journal of Clinical Oncology 35(15_suppl):6018-6018 DOI: 10.1200/JCO.2017.35.15_suppl.6018
  • Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retropsective analysis.(Presented at ESMO-Asia Conference , Singapore, Nov 2018) Annals of Oncology (2018) 29 (suppl_9): ix124-ix128. 10.1093/annonc/mdy443.

    Awards & Achievements

  • Selected for presentations of research work (with scholarship) at numerous National and International Conferences including ESMO-Asia (Singapore) and ELCC (Geneva).
  • Invited as Speaker and Faculty/Panelist at numerous State and National-level Oncology Conferences organised by Institutions.
  • Fellowship & Membership

  • Member of European Society of Medical Oncology
  • Indian Society of Medical and Paediatric Oncologist
  • American Society of Clinical Oncology
  • Languages Spoken

  • English
  • Hindi
  • Bengali
  • Field of Expertise

  • Medical aspects of Solid Tumours and Haemato-lymphoid Malignancies
  • Medical management of Oncologic emergencies
  • Immunotherapy and targeted therapies in treatment of advanced malignancies
  • Talks & Publications

  • RESEARCH : INTERNATIONAL PRESENTATIONS AND PUBLICATIONS:
  • Liquid Biopsies in Clinical Oncology: Review of validation results: K. Gupta, A.Chougule, V. Ramprasad, V. Noronha, A. Joshi, V. Patil, V.H. Veldore, K. Prabhash, Medical Oncology, Tata Memorial Centre Hospital, Mumbai, INDIA (Presented at ESMO-Asia, Nov 17-19, 2017 at Singapore): Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx672.001, Click Here
  • Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results K. Gupta, A. Joshi, V. Noronha, S.K. Parthiban, V.M. Patil, A. Janu, R. Kaushal, K. Prabhash; Medical Oncology, Tata Memorial Hospital Centre, Mumbai, INDIA ( Presented at ELCC, Geneva, April 11-14,2018): Journal of Thoracic Oncology Apr 2018 Volume 13, Issue 4, Supplement, Page S91
  • Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. K.Gupta, V. Noronha, A.Joshi, V.M. Patil, S.Parthiban, S.Srinivas, D.H.Vallathol, A.Mahajan, A.Janu, K.Prabhash May 2018, Journal of Clinical Oncology 36(15_suppl):e15065-e15065 DOI: 10.1200/JCO.2018.36.15_suppl.e15065
  • Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. Anant Ramaswamy, Vikas Ostwal, Kushal Gupta, et al. October 2018, South Asian Journal of Cancer 7(4):219 DOI: 10.4103/sajc.sajc_232_17
  • Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer (Co-author). Patil V, Joshi A, Noronha V, Dhumal S, et al.: Cancer Res Stat Treat 2018;1:46-50.
  • Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.(Co-author) May 2017 Journal of Clinical Oncology 35(15_suppl):6018-6018 DOI: 10.1200/JCO.2017.35.15_suppl.6018
  • Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retropsective analysis.(Presented at ESMO-Asia Conference , Singapore, Nov 2018) Annals of Oncology (2018) 29 (suppl_9): ix124-ix128. 10.1093/annonc/mdy443.

    Talks & Publications

  • RESEARCH : INTERNATIONAL PRESENTATIONS AND PUBLICATIONS:
  • Liquid Biopsies in Clinical Oncology: Review of validation results: K. Gupta, A.Chougule, V. Ramprasad, V. Noronha, A. Joshi, V. Patil, V.H. Veldore, K. Prabhash, Medical Oncology, Tata Memorial Centre Hospital, Mumbai, INDIA (Presented at ESMO-Asia, Nov 17-19, 2017 at Singapore): Annals of Oncology, Volume 28, Issue suppl_10, 1 November 2017, mdx672.001, Click Here
  • Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results K. Gupta, A. Joshi, V. Noronha, S.K. Parthiban, V.M. Patil, A. Janu, R. Kaushal, K. Prabhash; Medical Oncology, Tata Memorial Hospital Centre, Mumbai, INDIA ( Presented at ELCC, Geneva, April 11-14,2018): Journal of Thoracic Oncology Apr 2018 Volume 13, Issue 4, Supplement, Page S91
  • Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience. K.Gupta, V. Noronha, A.Joshi, V.M. Patil, S.Parthiban, S.Srinivas, D.H.Vallathol, A.Mahajan, A.Janu, K.Prabhash May 2018, Journal of Clinical Oncology 36(15_suppl):e15065-e15065 DOI: 10.1200/JCO.2018.36.15_suppl.e15065
  • Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. Anant Ramaswamy, Vikas Ostwal, Kushal Gupta, et al. October 2018, South Asian Journal of Cancer 7(4):219 DOI: 10.4103/sajc.sajc_232_17
  • Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer (Co-author). Patil V, Joshi A, Noronha V, Dhumal S, et al.: Cancer Res Stat Treat 2018;1:46-50.
  • Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.(Co-author) May 2017 Journal of Clinical Oncology 35(15_suppl):6018-6018 DOI: 10.1200/JCO.2017.35.15_suppl.6018
  • Outcomes of gemcitabine-docetaxel as second-line chemotherapy in patients of advanced soft tissue sarcoma: a retropsective analysis.(Presented at ESMO-Asia Conference , Singapore, Nov 2018) Annals of Oncology (2018) 29 (suppl_9): ix124-ix128. 10.1093/annonc/mdy443.
  • Awards & Achievements

  • Selected for presentations of research work (with scholarship) at numerous National and International Conferences including ESMO-Asia (Singapore) and ELCC (Geneva).
  • Invited as Speaker and Faculty/Panelist at numerous State and National-level Oncology Conferences organised by Institutions.
  • Fellowship & Membership

  • Member of European Society of Medical Oncology
  • Indian Society of Medical and Paediatric Oncologist
  • American Society of Clinical Oncology
  • Languages Spoken

  • English
  • Hindi
  • Bengali
  • Field of Expertise

  • Medical aspects of Solid Tumours and Haemato-lymphoid Malignancies
  • Medical management of Oncologic emergencies
  • Immunotherapy and targeted therapies in treatment of advanced malignancies
App floating icon
Appointment
Health Check
Homecare icon Home Care
Contact Us
Write to COO
Call Us